Sun Pharmaceutical Industries has reported results for fourth quarter and year ended March 31, 2022.
The company has reported net loss at Rs 1286.21 crore for the quarter under review as compared to net profit of Rs 184.88 crore for the same quarter in the previous year. However, total income of the company increased by 16.24% at Rs 4307.29 crore for Q4FY22 as compared Rs 3705.53 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported net loss at Rs 2222.36 crore for the quarter under review as compared to net profit of Rs 848.00 crore for the same quarter in the previous year. However, total income of the company increased by 10.73% at Rs 9560.35 crore for Q4FY22 as compared Rs 8633.98 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported net loss at Rs 99.99 crore as compared to net profit of Rs 842.40 crore for the previous year. However, total income of the company increased by 15.63% at Rs 16543.90 crore for year under review as compared to Rs 14308.12 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported a rise of 49.07% in its net profit at Rs 3405.82 crore as compared to Rs 2284.68 crore for the previous year. Total income of the company increased by 15.27% at Rs 39576.00 crore for year under review as compared to Rs 34333.66 crore for year ended March 31, 2021.
